148 related articles for article (PubMed ID: 38104783)
21. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
[TBL] [Abstract][Full Text] [Related]
22. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience.
Smile TD; Reddy CA; Qiao-Guan G; Winter WI; Stephans KL; Woody NM; Balagamwala EH; Amarnath SR; Magnelli A; AlHilli MM; Michener CM; Mahdi H; DeBernardo RL; Rose PG; Cherian SS
J Radiosurg SBRT; 2021; 7(3):189-197. PubMed ID: 33898082
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy for abdominal and pelvic oligometastases: Dosimetric targets for safe and effective local control.
Rwigema JM; King C; Wang PC; Kamrava M; Kupelian P; Steinberg ML; Lee P
Pract Radiat Oncol; 2015; 5(3):e183-e191. PubMed ID: 25413386
[TBL] [Abstract][Full Text] [Related]
25. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
[TBL] [Abstract][Full Text] [Related]
26. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
Fodor A; Broggi S; Incerti E; Dell'Oca I; Fiorino C; Samanes Gajate AM; Pasetti M; Cattaneo MG; Passoni P; Gianolli L; Calandrino R; Picchio M; Di Muzio N
Clin Lung Cancer; 2019 Jan; 20(1):e29-e38. PubMed ID: 30253920
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
28. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract][Full Text] [Related]
29. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
Kristensen CA; Nøttrup TJ; Berthelsen AK; Kjaer-Kristoffersen F; Ravn J; Sørensen JB; Engelholm SA
Radiother Oncol; 2009 Jul; 92(1):96-9. PubMed ID: 19364621
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
[TBL] [Abstract][Full Text] [Related]
34. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
36. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
[TBL] [Abstract][Full Text] [Related]
37. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
38. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
Facondo G; Vullo G; Valeriani M; Ascolese AM; De Sanctis V; Osti MF
Cancer Treat Res Commun; 2021; 29():100481. PubMed ID: 34700142
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
